McKesson Q1 Beats, Raises FY27 EPS View to $45 High-End
MCK sits 38% above its 52-week low of $637.
Summary
McKesson delivered a strong fiscal Q1, with revenue of $105.38B and adjusted EPS of $9.93, both comfortably ahead of consensus. The company raised its full-year adjusted EPS guidance to $44.20-$45.00, implying 13-15% growth, and boosted the quarterly dividend by 15%. Despite the strong adjusted results, the company revealed a fall in Q1 bottom line on a GAAP basis. Growth was driven by higher prescription volumes and specialty product distribution in the North American Pharmaceutical and Oncology segments. This follows the robust FY26 results and $7.7B buyback authorization announced in May, reinforcing the positive trajectory. The raised outlook and capital returns signal management's confidence in sustained momentum.
Updates
· SEC 10-Q — The 10-Q shows GAAP net income attributable to McKesson of $614M, diluted EPS of $5.15, and $136M in restructuring charges. Apollo Funds acquired a 13% stake in Medical-Surgical Solutions for $1.25B on June 1, 2026.
At the time of this announcement, MCK was trading at $880.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $102.7B. The 52-week trading range was $637.00 to $999.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.